- Home
- FEBO vs OCEA Comparison
FEBO vs OCEA Comparison
Compare FEBO & OCEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- OCEA
- Stock Information
- Founded
- FEBO 1993
- OCEA 2019
- Country
- FEBO Hong Kong
- OCEA United States
- Employees
- FEBO N/A
- OCEA N/A
- Industry
- FEBO
- OCEA Biotechnology: Pharmaceutical Preparations
- Sector
- FEBO
- OCEA Health Care
- Exchange
- FEBO Nasdaq
- OCEA Nasdaq
- Market Cap
- FEBO 19.4M
- OCEA 20.5M
- IPO Year
- FEBO 2023
- OCEA N/A
- Fundamental
- Price
- FEBO $1.47
- OCEA $0.47
- Analyst Decision
- FEBO
- OCEA
- Analyst Count
- FEBO 0
- OCEA 0
- Target Price
- FEBO N/A
- OCEA N/A
- AVG Volume (30 Days)
- FEBO 57.8K
- OCEA 631.6K
- Earning Date
- FEBO 10-03-2024
- OCEA 01-13-2025
- Dividend Yield
- FEBO N/A
- OCEA N/A
- EPS Growth
- FEBO N/A
- OCEA N/A
- EPS
- FEBO N/A
- OCEA N/A
- Revenue
- FEBO $16,319,897.00
- OCEA N/A
- Revenue This Year
- FEBO N/A
- OCEA N/A
- Revenue Next Year
- FEBO N/A
- OCEA N/A
- P/E Ratio
- FEBO N/A
- OCEA N/A
- Revenue Growth
- FEBO 9.01
- OCEA N/A
- 52 Week Low
- FEBO $1.20
- OCEA $0.43
- 52 Week High
- FEBO $17.68
- OCEA $7.79
- Technical
- Relative Strength Index (RSI)
- FEBO 41.24
- OCEA 34.89
- Support Level
- FEBO $1.54
- OCEA $0.53
- Resistance Level
- FEBO $1.72
- OCEA $0.70
- Average True Range (ATR)
- FEBO 0.21
- OCEA 0.08
- MACD
- FEBO -0.00
- OCEA -0.02
- Stochastic Oscillator
- FEBO 8.20
- OCEA 10.28
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About OCEA Ocean Biomedical Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.